1 00:00:00,000 --> 00:00:04,623 Gary Kadi: Hello and welcome back. Gary Cady here at the Delegate Podcast. I 2 00:00:04,623 --> 00:00:09,245 got a good one for you today. My guest today is Cody 3 00:00:09,245 --> 00:00:13,868 Simmons, co-founder and CEO of Dermosensor. Cody, we're so glad you're here. 4 00:00:13,868 --> 00:00:18,491 A guy who can spend eight years building the first automated skin 5 00:00:18,491 --> 00:00:23,113 cancer detection device cleared by the FDA for primary care doctors. It 6 00:00:23,113 --> 00:00:27,736 gives the answer in under 30 seconds. Time. 7 00:00:27,736 --> 00:00:32,845 called it one of the best in inventions in twenty twenty four and 8 00:00:32,845 --> 00:00:37,068 in twenty twenty five Inc. magazine, the most innovative invention, right? Cody welcome. 9 00:00:37,068 --> 00:00:38,048 Cody Simmons: Yeah, we're we're on 10 00:00:38,048 --> 00:00:41,901 the list alongside Anthropic and NVIDIA actually, which was was really cool. 11 00:00:41,901 --> 00:00:42,610 Gary Kadi: Yeah. 12 00:00:42,922 --> 00:00:44,953 Cody Simmons: Yeah, when I when I saw that, you know, you know 13 00:00:44,953 --> 00:00:46,985 you're gonna get the award ahead of time, but you don't 14 00:00:46,985 --> 00:00:47,285 know who else is. So yeah, no, it was 15 00:00:47,062 --> 00:00:48,821 Gary Kadi: Right. Yeah. 16 00:00:49,016 --> 00:00:52,976 Cody Simmons: quite an honor. We we don't belong there from a valuation standpoint, but 17 00:00:52,976 --> 00:00:56,935 it was innovative technology. So I I think we we certainly hold our 18 00:00:56,935 --> 00:01:01,194 Gary Kadi: A I you're certainly a humble man. I mean, you you know, it's it's 19 00:01:01,194 --> 00:01:04,334 pretty cool. Thirty under thirty Forbes too, my man. I mean, goodness gracious. 20 00:01:04,334 --> 00:01:05,680 Cody Simmons: Yeah, it was a it was a long time 21 00:01:05,680 --> 00:01:07,766 ago, but thank you. 22 00:01:07,766 --> 00:01:08,127 Gary Kadi: Yeah, 23 00:01:08,127 --> 00:01:11,702 well y I mean you couldn't tell by the way you 24 00:01:11,702 --> 00:01:12,002 Cody Simmons: I try, yeah. When you work in dermatology, you know, you gotta and live in Miami, 25 00:01:11,736 --> 00:01:15,346 Gary Kadi: take care of yourself, so you're doing pretty darn good. 26 00:01:15,591 --> 00:01:19,032 Cody Simmons: you gotta gotta try keeping youthful look. 27 00:01:19,032 --> 00:01:22,661 Gary Kadi: By the way, was is that by accident? I was when I 28 00:01:22,661 --> 00:01:26,291 was looking at my notes, I'm like he's doing dermosensor and he's 29 00:01:26,291 --> 00:01:27,412 in Miami. Was that was that by design or was that Okay. 30 00:01:27,412 --> 00:01:30,265 Cody Simmons: It's just coincidence. Nah, yeah. Well, so 31 00:01:30,485 --> 00:01:34,420 so yeah, as a bit of an interesting founding story, you know, 32 00:01:34,420 --> 00:01:38,355 we're a bit unique actually, because so my co-founder, Dr. Maurice Foray, 33 00:01:38,355 --> 00:01:42,290 very successful serial medical device entrepreneur and executive. so he came across 34 00:01:42,290 --> 00:01:46,225 this technology. He's been on the board of trustees for I think 35 00:01:46,225 --> 00:01:50,160 20 plus years. It's where he went to medical school at Boston 36 00:01:50,160 --> 00:01:54,095 University. so the spectroscopy technology was developed out of BU. 37 00:01:54,095 --> 00:01:54,395 And 38 00:01:54,168 --> 00:01:54,532 Gary Kadi: Nice. 39 00:01:54,755 --> 00:01:59,376 Cody Simmons: so actually they formed the company. I was still an undergrad. but then several 40 00:01:59,376 --> 00:02:03,998 years later, so there was never kind of any full-time employees, or you know, 41 00:02:03,998 --> 00:02:08,619 it's kind of some early data collection, almost think of it like a a 42 00:02:08,619 --> 00:02:11,971 privately funded SBIR grant, right? Kind of early academic exploratory work. 43 00:02:11,971 --> 00:02:12,271 Gary Kadi: Right. 44 00:02:13,240 --> 00:02:18,007 Cody Simmons: and so, you know, and I did my graduate work in in bioengineering at 45 00:02:18,007 --> 00:02:22,774 Stanford and then was at Genentech for four years, mostly focused on oncology. 46 00:02:22,774 --> 00:02:26,896 And then it was head of business development at a similar startup that 47 00:02:26,896 --> 00:02:31,018 was doing had kind of screening and monitoring tools for frontline providers and 48 00:02:31,018 --> 00:02:35,140 patients at home. And a good friend of mine from college, he was 49 00:02:35,140 --> 00:02:39,118 actually my 20 years ago, my TA in an entrepreneurship class. 50 00:02:39,118 --> 00:02:39,418 Gary Kadi: Hmm. 51 00:02:39,442 --> 00:02:42,857 Cody Simmons: ended up becoming good friends with them. And you we stayed in close 52 00:02:42,857 --> 00:02:46,273 touch. I actually lived with him the first year. I I lived in 53 00:02:46,273 --> 00:02:49,688 Miami a decade ago. so we were roommates for a year. 54 00:02:49,688 --> 00:02:55,714 He knew Maurice well. Maurice was an investor in his health tech fund here in Miami. And 55 00:02:55,714 --> 00:02:56,020 Gary Kadi: Mm-hmm. 56 00:02:56,192 --> 00:02:59,011 Cody Simmons: he's like, Hey, you gotta meet this guy. You know, I 57 00:02:59,011 --> 00:03:01,830 know you've had, you know, you've talked about how you've had 58 00:03:01,830 --> 00:03:04,649 skin biopsies. My first one, Gary, was as a teenager growing 59 00:03:04,649 --> 00:03:06,893 up playing tennis in Florida. So there's the Florida piece. 60 00:03:06,893 --> 00:03:07,285 Gary Kadi: I see. 61 00:03:07,548 --> 00:03:10,676 Cody Simmons: my mom and my aunt both had melanoma. Fortunately, early stage, 62 00:03:10,676 --> 00:03:13,805 totally fine. So, you know, personally it was something I was 63 00:03:13,805 --> 00:03:16,450 very aware of and my family was very attuned to. 64 00:03:16,450 --> 00:03:16,840 Gary Kadi: Right. 65 00:03:18,518 --> 00:03:22,047 Cody Simmons: So, you know, I I kind of hats off to to my 66 00:03:22,047 --> 00:03:25,577 friend of the last 20 years, Christian Seal, who's like, wait, I 67 00:03:25,577 --> 00:03:29,106 know a big shot entrepreneur that has a skin can you know, 68 00:03:29,106 --> 00:03:32,635 cool skin cancer tech, and they're looking for someone to quote Maurice 69 00:03:32,635 --> 00:03:36,165 when I first spoke with them over 10 years ago. They're looking 70 00:03:36,165 --> 00:03:39,694 for someone to turn their research project into a company. 71 00:03:39,694 --> 00:03:40,096 Gary Kadi: Mm. 72 00:03:40,230 --> 00:03:43,647 Cody Simmons: So that's kind of where I got involved. We went from this, 73 00:03:43,647 --> 00:03:47,065 you know, microwave size desktop spectroscopy system we built with BU. 74 00:03:47,065 --> 00:03:51,606 To this one pound handheld non-invasive device. 75 00:03:51,606 --> 00:03:52,598 Gary Kadi: Mm. 76 00:03:52,598 --> 00:03:56,403 Cody Simmons: and that was really the vision is okay, can you bring, you 77 00:03:56,403 --> 00:04:00,209 know, powerful diagnostic capabilities for skin cancer and put that in the 78 00:04:00,209 --> 00:04:03,287 hands of frontline providers, eventually patients at home, because skin cancer 79 00:04:03,287 --> 00:04:03,665 Gary Kadi: Mm-hmm. 80 00:04:04,014 --> 00:04:07,110 Cody Simmons: is the only cancer type you can always see, right? 81 00:04:07,110 --> 00:04:07,410 And that's really our focus. Let's let's avoid all 82 00:04:07,319 --> 00:04:10,001 Gary Kadi: Mm-hmm. 83 00:04:10,207 --> 00:04:14,817 Cody Simmons: deaths from the cancer that you can literally see, right? 84 00:04:14,817 --> 00:04:15,144 Gary Kadi: Yeah. 85 00:04:15,648 --> 00:04:20,629 Cody Simmons: And so that's, you know, the focus and and really the approach in doing 86 00:04:20,629 --> 00:04:25,609 that. you know, there's been companies in the past that have really focused on 87 00:04:25,609 --> 00:04:30,273 dermatologists, but dermatologists by definition are specialized, are expert in dermatology. They're already 88 00:04:30,273 --> 00:04:30,588 Gary Kadi: Right. 89 00:04:30,590 --> 00:04:33,089 Cody Simmons: pretty good at dermatology. Go figure, right? 90 00:04:33,089 --> 00:04:33,389 Gary Kadi: Yep. 91 00:04:34,133 --> 00:04:39,631 Cody Simmons: of course, every expert and specialist can further improve their expertise and 92 00:04:39,631 --> 00:04:45,130 and but by and large, they're already pretty darn good at dermatology. 93 00:04:45,130 --> 00:04:51,149 So the challenge the challenge though is only about eight percent of the hundred million 94 00:04:51,149 --> 00:04:56,556 Americans at risk for skin cancer actually get the recommended annual skin exam. So that's 95 00:04:56,556 --> 00:04:56,914 Gary Kadi: Right. 96 00:04:57,168 --> 00:05:00,983 Cody Simmons: the big challenge, is like someone like me that, you know, has family 97 00:05:00,983 --> 00:05:04,798 members that have had skin cancer, that has, you know, 80 to 100 98 00:05:04,798 --> 00:05:08,614 plus moles on their body. if all of those people tried to go 99 00:05:08,614 --> 00:05:11,948 to dermatologist every year, they couldn't, right? There's already months 100 00:05:11,948 --> 00:05:12,297 Gary Kadi: Right. 101 00:05:12,429 --> 00:05:14,390 Cody Simmons: long wait times of many of them. 102 00:05:14,390 --> 00:05:14,690 And only 103 00:05:14,625 --> 00:05:14,925 Gary Kadi: Mm. 104 00:05:14,940 --> 00:05:20,877 Cody Simmons: around 10 million of the hundred million out-risk Americans actually get the recommended annual skin exam. 105 00:05:20,877 --> 00:05:21,595 Gary Kadi: Mm. 106 00:05:21,595 --> 00:05:23,552 Cody Simmons: So that's what it's really a public health problem 107 00:05:23,552 --> 00:05:25,004 when you think about it, or like a dermatology 108 00:05:25,004 --> 00:05:25,330 Gary Kadi: Yeah. 109 00:05:25,508 --> 00:05:28,866 Cody Simmons: capacity problem, right? Like, okay, skin cancer 110 00:05:28,866 --> 00:05:29,166 Gary Kadi: Yeah. 111 00:05:29,220 --> 00:05:33,762 Cody Simmons: is visible, you can see it, but how do you actually effectively check it? So that's 112 00:05:33,762 --> 00:05:34,062 Gary Kadi: Right. 113 00:05:34,414 --> 00:05:39,186 Cody Simmons: that's the challenge we've been tackling. And we didn't come up with a solution in 114 00:05:39,186 --> 00:05:43,959 terms of the approach. So for decades, primary care, dermatology, public health are like, 115 00:05:43,959 --> 00:05:46,988 Let's just upskill non-dermatologists. But 116 00:05:46,988 --> 00:05:47,314 Gary Kadi: Right. 117 00:05:47,431 --> 00:05:51,292 Cody Simmons: by definition, non-dermatologists are not dermatologists and they didn't spend the 118 00:05:51,292 --> 00:05:55,152 hundreds or thousands of hours training and assessing suspicious skin lesions 119 00:05:55,152 --> 00:05:59,013 and how to diagnose them, et cetera. And they don't have 120 00:05:59,013 --> 00:06:02,873 the time, you know, they're responsible for thousands of different diseases. 121 00:06:02,873 --> 00:06:04,725 They can't specialize in dermatology, right? Because they're not dermatologists. So 122 00:06:04,725 --> 00:06:06,532 Gary Kadi: Exactly. Yep. 123 00:06:06,734 --> 00:06:09,726 Cody Simmons: that was really our can we put the eyes of 124 00:06:09,726 --> 00:06:12,718 a dermatologist in the hands of hundreds of thousands of 125 00:06:12,718 --> 00:06:20,598 Frontline providers think family doctors, internists, OBGYNs, nurses at CBS Mediclinics, right? Pharmacists, 126 00:06:20,598 --> 00:06:27,969 anyone that a patient currently asks, or Gary, they could ask, Hey, what 127 00:06:27,969 --> 00:06:28,403 Gary Kadi: Mm-hmm. 128 00:06:28,478 --> 00:06:30,836 Cody Simmons: do you think about this suspicious mole? Should I 129 00:06:30,836 --> 00:06:31,499 go see a dirt? Right? Like there's even news 130 00:06:31,499 --> 00:06:33,105 Gary Kadi: Right. Right. 131 00:06:33,194 --> 00:06:37,653 Cody Simmons: articles of like, hey, a hairstylist found the melanoma on my head. Right? Like there's crazy story. 132 00:06:37,653 --> 00:06:40,849 Gary Kadi: Inside. Yeah. Yeah. 133 00:06:40,856 --> 00:06:43,224 Cody Simmons: Yeah. And 134 00:06:43,224 --> 00:06:46,602 So, you know, our fur first focus is obviously physicians who currently already 135 00:06:46,602 --> 00:06:49,979 do this as part of their scope of practice. Right. Like when you 136 00:06:49,979 --> 00:06:53,356 ask your doctor, hey, what do you think about this mobile shy gooseoderm? 137 00:06:53,356 --> 00:06:55,937 They they can't really abstain, right? They can't be like, 138 00:06:55,937 --> 00:06:56,829 Gary Kadi: Right. Right. 139 00:06:56,984 --> 00:07:00,413 Cody Simmons: I I don't know, you decide on your own. It's like, wait, what? 140 00:07:00,413 --> 00:07:03,842 You know, so it it's part of their scope of practice to make 141 00:07:03,842 --> 00:07:07,271 those decisions, but studies show they miss up to half of those cancers. 142 00:07:07,271 --> 00:07:10,700 And they're also doing, depending on what study you read, 20 to 40. 143 00:07:10,700 --> 00:07:13,995 Referrals or biopsies for every one melanoma. 144 00:07:14,493 --> 00:07:19,286 So, like only, you know, two to three percent of the referrals and biopsies 145 00:07:19,286 --> 00:07:23,671 they're doing for suspicion for melanoma are actually melanoma. So the other 90 146 00:07:23,671 --> 00:07:23,971 Gary Kadi: Right. 147 00:07:24,080 --> 00:07:28,836 Cody Simmons: plus percent are unnecessary. So that's really where our big focus is you 148 00:07:28,836 --> 00:07:33,591 know, helping them detect more cancer and also avoiding unnecessary referrals and biopsies. 149 00:07:33,591 --> 00:07:38,347 So that's a key thing to start with, right? Kind of better equipping. 150 00:07:38,347 --> 00:07:42,319 clinicians that are already doing skin checks to some degree. But then 151 00:07:42,319 --> 00:07:46,291 the kind of the next phase is how can we equip healthcare 152 00:07:46,291 --> 00:07:50,263 professionals and maybe eventually even patients at home that are not currently 153 00:07:50,263 --> 00:07:51,853 involved in doing skin checks, right? At least formally like 154 00:07:51,853 --> 00:07:54,225 Gary Kadi: Mm-hmm. 155 00:07:54,235 --> 00:07:56,851 Cody Simmons: pharmacists or aestheticians or even, you know, I don't know, barbers. 156 00:07:56,851 --> 00:07:59,467 You know, I I use that example because there are real 157 00:07:59,467 --> 00:08:01,678 stories about that. I don't know how the FDA 158 00:08:01,678 --> 00:08:01,978 Gary Kadi: Right. 159 00:08:02,083 --> 00:08:08,119 Cody Simmons: would ultimately feel about that. But yeah, that that, you know, examples of of kind 160 00:08:08,119 --> 00:08:10,305 our philosophy in where we're 161 00:08:10,305 --> 00:08:13,748 Gary Kadi: Well, first of all, thank you for creating this because I think 162 00:08:13,748 --> 00:08:17,190 about all the peoples whose lives will be transformed because you took 163 00:08:17,190 --> 00:08:20,632 a research project and turned it into a company and now bringing 164 00:08:20,632 --> 00:08:24,075 it alive and having a solution for people to to address this. 165 00:08:24,075 --> 00:08:27,518 The gap between the actual number of people who have moles and 166 00:08:27,518 --> 00:08:30,960 and and suspicious items on their skin to the people that actually 167 00:08:30,960 --> 00:08:34,403 get it diagnosed. I know myself, I'm a sun worshiper. I love 168 00:08:34,403 --> 00:08:36,866 the sun and I had a mole right here. 169 00:08:36,866 --> 00:08:37,976 Cody Simmons: I was out to say, you 170 00:08:37,976 --> 00:08:41,825 you have a you have a good tan, but I wasn't gonna compliment 171 00:08:41,825 --> 00:08:43,273 you. I was gonna give you some crap about that. I you I 172 00:08:43,273 --> 00:08:45,613 Gary Kadi: I no, no, and and appropriately so. 173 00:08:45,674 --> 00:08:50,775 Cody Simmons: used to have a good tan. Pre-derma sensor, I was all about having a a tan. 174 00:08:50,775 --> 00:08:54,360 Gary Kadi: Yeah. Yeah, no, I'm here on Cape Cod. So like, you know, beach 175 00:08:54,360 --> 00:08:57,946 is like, you know, my sec I'm in podcast room and I'm on 176 00:08:57,946 --> 00:09:01,532 the beach, you know, with my family. So, but I do wear sunscreen. 177 00:09:01,532 --> 00:09:05,117 It is a long summer here, but I do want to say, like, 178 00:09:05,117 --> 00:09:08,702 when when I had that mole, it was non-cancerous, but like I didn't 179 00:09:08,702 --> 00:09:11,083 want to confront it, Cody, right? I I know my own experience. 180 00:09:11,083 --> 00:09:11,754 Cody Simmons: Mm-hmm. 181 00:09:12,288 --> 00:09:14,616 Gary Kadi: I didn't want to come face to face and have that 182 00:09:14,616 --> 00:09:16,226 answer, you know, and I happen to be at a 183 00:09:16,226 --> 00:09:16,978 Cody Simmons: Was it was it 184 00:09:16,978 --> 00:09:19,337 like kind of a fear or concern, or was it just 185 00:09:19,337 --> 00:09:21,213 you didn't have time, you didn't want to deal with going 186 00:09:21,213 --> 00:09:21,697 Gary Kadi: No, it was a fear. I didn't want the answer. 187 00:09:21,697 --> 00:09:24,056 Cody Simmons: to get a biopsy? It was a fear, yeah. 188 00:09:24,393 --> 00:09:27,476 Gary Kadi: I I, you know, lived and I'm I'm as you were sharing, 189 00:09:27,476 --> 00:09:29,985 I was living in my own experience of it. And my 190 00:09:29,985 --> 00:09:30,285 Cody Simmons: Yeah. 191 00:09:30,713 --> 00:09:33,931 Gary Kadi: I went in for I forgot a blood, I think it was a 192 00:09:33,931 --> 00:09:37,150 you had a blood draw and my my my primary care said, Hey, 193 00:09:37,150 --> 00:09:39,779 you should probably go look at that. You know, it does it looks 194 00:09:39,779 --> 00:09:40,320 Cody Simmons: Yeah, yeah. 195 00:09:40,368 --> 00:09:43,360 Gary Kadi: fine, but you should go look at it. And when I went 196 00:09:43,360 --> 00:09:46,353 and yeah, they said let's take it off. you know, it's so 197 00:09:46,593 --> 00:09:50,576 You know, ever since then, I and and when I saw that we 198 00:09:50,576 --> 00:09:54,559 were going to talk today, I really looked at your website and did 199 00:09:54,559 --> 00:09:58,542 my research and really saw like I wasn't sure how you were approaching 200 00:09:58,542 --> 00:10:02,525 this, right? And I really love that you're really giving access to people 201 00:10:02,525 --> 00:10:06,508 to save people's lives that wouldn't normally have that access. But not only 202 00:10:06,508 --> 00:10:10,491 for the practitioner, Cody, what I'm experiencing and listening to is for the 203 00:10:10,491 --> 00:10:14,474 patient who, like me, was in avoidance about things. 204 00:10:14,474 --> 00:10:17,456 Right, and wouldn't do my regular screening. Now I go every year because 205 00:10:17,456 --> 00:10:17,756 of that, but I really wanna acknowledge you for that, you know. 206 00:10:17,568 --> 00:10:20,840 Cody Simmons: Now you're good about it. Thank 207 00:10:20,840 --> 00:10:25,990 you. And and Gary, it's it's interesting you share that story because 208 00:10:25,990 --> 00:10:31,141 and and just wild statistically, but the second patient that was ever 209 00:10:31,141 --> 00:10:33,536 scanned with our device following FDA approval was exactly your profile. so 210 00:10:33,536 --> 00:10:36,618 Gary Kadi: Yeah. Yeah. 211 00:10:36,618 --> 00:10:42,075 Cody Simmons: I I don't know any identifiable information anyway, but it was an 212 00:10:42,075 --> 00:10:47,532 elderly, elderly Caucasian gentleman that the first user, Dr. Kevin Wong. 213 00:10:47,532 --> 00:10:50,830 In Pennsylvania. he was the first person to have got a 214 00:10:50,830 --> 00:10:52,384 device in the US in May 2024. And he said his 215 00:10:52,384 --> 00:10:54,046 Gary Kadi: Hmm. Hmm. 216 00:10:54,128 --> 00:10:57,786 Cody Simmons: second patient, a couple of weeks after getting the device, his second 217 00:10:57,786 --> 00:11:01,443 patient, older guy, had some well, I think he said it was 218 00:11:01,443 --> 00:11:05,101 on his like upper torso. And he's like, Yeah, I've had it 219 00:11:05,101 --> 00:11:08,759 for a couple of years. I'm not worried about it, it's fine. 220 00:11:08,759 --> 00:11:12,416 And he's like, This really looks like a clear-cut case of melanoma. 221 00:11:12,416 --> 00:11:16,074 I'm worried about it. I want you to go see a dermatologist. 222 00:11:16,074 --> 00:11:18,136 And he's like, the guy was arguing with him. He's like, I don't 223 00:11:18,136 --> 00:11:19,797 want to deal with that. I'm sure it's fine. I don't want 224 00:11:19,797 --> 00:11:20,146 Gary Kadi: Yeah. 225 00:11:20,197 --> 00:11:23,174 Cody Simmons: to go. And he's like, well, you know, good news is we 226 00:11:23,174 --> 00:11:26,152 just got this new device in literally two weeks ago. Let's go 227 00:11:26,152 --> 00:11:29,130 ahead and scan it. It gives a zero to 10 risk scale 228 00:11:29,130 --> 00:11:31,627 for skin cancer. And it was just approved by 229 00:11:31,627 --> 00:11:31,955 Gary Kadi: Yeah. 230 00:11:32,107 --> 00:11:35,285 Cody Simmons: the FDA. There's, you know, two published studies of the many studies 231 00:11:35,285 --> 00:11:38,462 show it's as accurate as in-person dermatologists. Let's go ahead and scan 232 00:11:38,462 --> 00:11:40,758 it. And the result was 10 out of 10. And which in 233 00:11:40,758 --> 00:11:41,640 Gary Kadi: Right. 234 00:11:41,640 --> 00:11:44,818 Cody Simmons: our pivotal study was a 61% chance of being cancer. 235 00:11:45,518 --> 00:11:49,072 Yeah. And so the doctor's like I was immediately not only 236 00:11:49,072 --> 00:11:52,626 immediately able to convince him to go, but I also called 237 00:11:52,626 --> 00:11:56,179 up a local dermatologist who instead of a couple month wait 238 00:11:56,179 --> 00:11:58,451 time was able to see him a week later. And 239 00:11:58,451 --> 00:11:59,667 Gary Kadi: Mm, beautiful. 240 00:11:59,733 --> 00:12:02,945 Cody Simmons: it was yeah, and it was biopsy and diagnosed melanoma. So yeah. 241 00:12:02,945 --> 00:12:04,906 Gary Kadi: Well, amazing. So that's 242 00:12:04,906 --> 00:12:08,097 really where I'm sitting in. I'm sitting in this is a life 243 00:12:08,097 --> 00:12:11,287 changing device, but it it's a mission beyond that. but I want 244 00:12:11,287 --> 00:12:14,478 to zoom out for our entrepreneurs that are with us today, because 245 00:12:14,478 --> 00:12:17,669 that's our group, and I want to get into the entrepreneurial build 246 00:12:17,669 --> 00:12:20,860 of this thing and like into your world and sharing your experience. 247 00:12:20,860 --> 00:12:24,050 And I'm gonna I'm gonna go over four areas. We're gonna talk 248 00:12:24,050 --> 00:12:27,241 about regulation, we're gonna talk about capital, we're gonna talk about trust, 249 00:12:27,241 --> 00:12:30,432 and we're gonna talk about scale. 250 00:12:30,432 --> 00:12:34,524 The first question is in inside of regulation. You know, you keep talking about FDA. 251 00:12:34,524 --> 00:12:38,617 I keep sitting here going, man, this poor guy. He was sitting there for eight 252 00:12:38,617 --> 00:12:44,090 years, tens of millions of bucks before he could sell unit one. 253 00:12:44,090 --> 00:12:49,564 How did you keep together a team that long with no revenue? 254 00:12:49,564 --> 00:12:54,832 and and keep the mission and mit and vision and and and and just everybody 255 00:12:54,832 --> 00:12:59,277 taking steps forward to bring this to market. Let's let's zoom out and go there. 256 00:12:59,277 --> 00:13:00,848 Cody Simmons: Yep. 257 00:13:00,848 --> 00:13:05,390 Yeah, I mean I I think the healthcare is hard, hardware is hard, 258 00:13:05,390 --> 00:13:09,931 and dealing with the FDA or any major regulator is hard, right? People 259 00:13:09,931 --> 00:13:13,856 people commonly say each of those, and we did all three, right? 260 00:13:13,856 --> 00:13:14,214 Gary Kadi: Right. 261 00:13:14,553 --> 00:13:19,398 Cody Simmons: Healthcare, hardware, and FDA. So, you know, it's a very tough space. that 262 00:13:19,398 --> 00:13:24,242 being said, I think the big benefit that medical devices and biopharma, you 263 00:13:24,242 --> 00:13:29,087 know, as a genetic for a few years, have going for them. 264 00:13:29,087 --> 00:13:33,160 And you know, for our device and and focus especially, is 265 00:13:33,160 --> 00:13:36,758 it's such an inspiring and engaging mission and vision, right? And 266 00:13:36,758 --> 00:13:37,058 Gary Kadi: Right. 267 00:13:37,232 --> 00:13:41,027 Cody Simmons: that's part of what drove me to it instead of finance, or you know, 268 00:13:41,027 --> 00:13:44,823 was certainly you can ultimately do well financially if you do well, sure, but 269 00:13:44,823 --> 00:13:48,234 you're also really bettering the world and impacting the world, right? And 270 00:13:48,234 --> 00:13:48,534 Gary Kadi: Right. 271 00:13:48,807 --> 00:13:52,784 Cody Simmons: you know, my my both my parents were kind of educators, 272 00:13:52,784 --> 00:13:56,760 and you know, that was always something I guess just 273 00:13:56,760 --> 00:14:00,909 innately we were kind of raised with is your job should align with 274 00:14:00,909 --> 00:14:05,059 kind of your moral compass and kind of make making the world better. 275 00:14:05,059 --> 00:14:09,208 and so honestly I think it was kind of attracting like minded people 276 00:14:09,208 --> 00:14:13,357 to the company that understood, hey, this could end up being a long 277 00:14:13,357 --> 00:14:17,506 slog. May never even happen, right? A lot of academic researchers and even 278 00:14:17,506 --> 00:14:21,656 researchers within big pharma companies go their entire career without ever having worked 279 00:14:21,656 --> 00:14:25,805 on a drug that gets approved in 280 00:14:26,047 --> 00:14:27,148 patients, right? Some go their 281 00:14:27,148 --> 00:14:27,551 Gary Kadi: Right. 282 00:14:27,598 --> 00:14:31,163 Cody Simmons: their entire lives. and you know, you never know at the end 283 00:14:31,163 --> 00:14:34,729 of that journey do you actually get FDA approval, right? So you 284 00:14:34,729 --> 00:14:38,294 know, roughly the eight years. So I'm 10 years in now, two 285 00:14:38,294 --> 00:14:41,859 years commercial, first eight years were R D. And so we started 286 00:14:41,859 --> 00:14:45,424 with that large device. If I was at my my office office 287 00:14:45,424 --> 00:14:48,990 versus my home office, it's it's behind me against the wall. So 288 00:14:48,990 --> 00:14:52,555 sorry you can't can't see it, but it's 289 00:14:52,555 --> 00:14:55,671 yeah, the idea was, you know, a year, year and a half to 290 00:14:55,671 --> 00:14:58,788 miniaturize it, maybe a couple years to run the study, and then a 291 00:14:58,788 --> 00:15:01,904 few month FDA approval process. So that was the hope in the beginning 292 00:15:01,904 --> 00:15:04,385 be, you know, three years, maybe four years. Ended up three 293 00:15:04,385 --> 00:15:04,685 Gary Kadi: Yeah. 294 00:15:05,021 --> 00:15:07,649 Cody Simmons: years to miniaturize it, 295 00:15:07,649 --> 00:15:07,949 Gary Kadi: Wow. 296 00:15:08,015 --> 00:15:10,294 Cody Simmons: miniaturize it and kind of make the robust design to where it could be actually 297 00:15:10,294 --> 00:15:10,936 Gary Kadi: How big was 298 00:15:10,936 --> 00:15:12,891 it? Can you hold that up just so we can 299 00:15:12,891 --> 00:15:13,495 see so we can so that's the unit itself. 300 00:15:13,495 --> 00:15:15,035 Cody Simmons: So this is the current device. 301 00:15:15,035 --> 00:15:18,906 H yeah, here here's my smartphone for comparison, right? Here's my iPhone. 302 00:15:18,906 --> 00:15:19,702 So it's about the size of an iPhone. Yeah, kinda little. it's 303 00:15:19,702 --> 00:15:22,776 Gary Kadi: wow. Is that a is that a pro, a sixteen 304 00:15:22,776 --> 00:15:24,995 Cody Simmons: a air, yeah. So I think in between the Pro and the 305 00:15:24,995 --> 00:15:26,647 Gary Kadi: pro or something like that? It's pretty. Yeah. Yep. 306 00:15:26,647 --> 00:15:30,517 Cody Simmons: Max Plus or whatever the name of it. But 307 00:15:30,517 --> 00:15:34,666 yep. And so we yeah, so three years to miniaturize what was 308 00:15:34,666 --> 00:15:38,816 a a microwave size or printer size. Yeah, it's it's actually a 309 00:15:38,816 --> 00:15:42,698 little bigger than that white printer in my bookshelf back there. 310 00:15:42,698 --> 00:15:43,282 Gary Kadi: Wow. 311 00:15:43,282 --> 00:15:43,850 Wow. 312 00:15:43,850 --> 00:15:45,040 Cody Simmons: so miniaturizing 313 00:15:45,201 --> 00:15:48,562 miniaturizing that to this. and we're talking with a big tech company 314 00:15:48,562 --> 00:15:51,924 and and some design firms about, hey, let's make a next gen 315 00:15:51,924 --> 00:15:55,285 device that's, you know, the size of a thick pen and can 316 00:15:55,285 --> 00:15:58,305 plug into the bottom of your phone. And, you know. So 317 00:15:58,305 --> 00:15:58,605 Gary Kadi: Right. 318 00:15:58,646 --> 00:16:04,103 Cody Simmons: yeah, so excited about kind of future miniaturization too. But so that 319 00:16:04,103 --> 00:16:08,992 took three years. Doing all the studies took four years, and 320 00:16:08,992 --> 00:16:09,371 Gary Kadi: Mm. 321 00:16:09,560 --> 00:16:11,615 Cody Simmons: then the FDA approval process took one year. So that's kind of how they 322 00:16:11,615 --> 00:16:12,896 Gary Kadi: Oof. Man, you 323 00:16:14,217 --> 00:16:17,606 man, bless you for that, man. That is really strong leadership. And what 324 00:16:17,606 --> 00:16:20,995 I heard, the insight here I want to highlight for our entrepreneurs is 325 00:16:20,995 --> 00:16:24,384 really setting expectations with your employees. That's what I heard is the number 326 00:16:24,384 --> 00:16:27,773 one thing that that really made this work. You said, hey, this is 327 00:16:27,773 --> 00:16:31,162 gonna be a long slog, but it has a high purpose and a 328 00:16:31,162 --> 00:16:34,551 high impact. So you had the purpose in there, but you also had 329 00:16:34,551 --> 00:16:37,940 expectations. And I think that that's really important in the hiring process. So 330 00:16:37,940 --> 00:16:41,329 you've got somebody who really has a humanist root. 331 00:16:41,523 --> 00:16:45,106 root in their in their soul, but they also know that this 332 00:16:45,106 --> 00:16:48,688 isn't gonna be like, you know, quick hits and likes on, you 333 00:16:48,688 --> 00:16:52,271 know, on social media. This is like, you know, you're gonna you're 334 00:16:52,271 --> 00:16:54,723 creating something for the for the future. And did you have someone 335 00:16:54,723 --> 00:16:55,539 Cody Simmons: Yeah. 336 00:16:55,854 --> 00:16:58,755 Gary Kadi: stay for for the eight years? 337 00:16:58,755 --> 00:17:00,789 Cody Simmons: There's three of us actually. So yeah, 338 00:17:00,789 --> 00:17:01,202 Gary Kadi: Great. 339 00:17:01,257 --> 00:17:06,413 Cody Simmons: our COO, Ryan Freedon, he joined eight months after I did. So brought him on. 340 00:17:06,413 --> 00:17:11,242 Cause the kind of founders are, you know, they're not too technical and I 341 00:17:11,242 --> 00:17:11,542 Gary Kadi: Yeah. 342 00:17:11,569 --> 00:17:14,953 Cody Simmons: have a engineering background, but I never was an engineer. You know, so I 343 00:17:14,953 --> 00:17:15,406 Gary Kadi: I say 344 00:17:15,406 --> 00:17:18,676 Cody Simmons: but I, you know, know enough to talk shop with the real engineers. So 345 00:17:18,676 --> 00:17:18,976 Gary Kadi: Right. 346 00:17:19,069 --> 00:17:21,860 Cody Simmons: kind of got on board, started taking with engineers. I'm like, 347 00:17:21,860 --> 00:17:23,625 this is not gonna be one year. Like that this 348 00:17:23,625 --> 00:17:24,540 Gary Kadi: Yeah. Yeah. 349 00:17:24,652 --> 00:17:28,717 Cody Simmons: is not some quick and easy thing a as we were hoping it may be. 350 00:17:28,717 --> 00:17:32,842 So then I involved so Ryan's background had actually been involved in mechatronic, 351 00:17:32,842 --> 00:17:36,968 right? mechanical devices, electronic devices, miniaturization. He actually he probably wouldn't like me 352 00:17:36,968 --> 00:17:41,093 talking about it. He calls it his his claim to shame. He was 353 00:17:41,093 --> 00:17:45,218 his first startup, he's done like five before this, was one of the 354 00:17:45,218 --> 00:17:49,343 first e-cigarette companies. And they were shipping tens of thousands of and he 355 00:17:49,343 --> 00:17:53,469 said as like, you know, we're as one of the first ones, like 356 00:17:53,469 --> 00:17:57,594 we actually did have noble intentions, which was to help avoid 357 00:17:57,594 --> 00:18:02,153 harmful smoking. You know, he didn't know what it would turn into ultimately. But 358 00:18:02,153 --> 00:18:02,453 Gary Kadi: Yeah. 359 00:18:03,317 --> 00:18:06,979 Cody Simmons: so yeah, he had been involved with some of the, you 360 00:18:06,979 --> 00:18:10,641 know, kind of high volume mechatronic kind of systems. So so 361 00:18:10,641 --> 00:18:14,303 he joined and knew a lot of software work. So he 362 00:18:14,303 --> 00:18:17,965 joined and then a couple months after him was our I 363 00:18:17,965 --> 00:18:21,627 think at the time director, associate director of clinical operations, who 364 00:18:21,627 --> 00:18:24,671 now, nine years later, is our VP of clinical affairs, Justin 365 00:18:24,671 --> 00:18:24,973 Gary Kadi: Yep. 366 00:18:25,289 --> 00:18:26,317 Cody Simmons: Fraser. 367 00:18:26,317 --> 00:18:26,617 So yeah, kinda 368 00:18:26,529 --> 00:18:26,829 Gary Kadi: Yeah. 369 00:18:27,038 --> 00:18:31,319 Cody Simmons: us three we're the the first three team members have actually been working 370 00:18:31,319 --> 00:18:34,946 together now for over nine years. And and and along with all the 371 00:18:34,946 --> 00:18:35,550 Gary Kadi: congrats. 372 00:18:35,600 --> 00:18:41,735 Cody Simmons: board members, we've only added one new board director in the last nine years also. 373 00:18:41,735 --> 00:18:45,305 Gary Kadi: Awesome. So now I want to move to capital because I know you just got a capital 374 00:18:45,305 --> 00:18:45,605 Cody Simmons: Sure. 375 00:18:45,997 --> 00:18:50,217 Gary Kadi: raise. And I but I like getting behind the scenes, right? Here 376 00:18:50,217 --> 00:18:54,437 you are, you have a version, a big monster version of this 377 00:18:54,437 --> 00:18:58,657 machine that really has a high, you know, clear value. But how 378 00:18:58,657 --> 00:19:02,877 do you raise money when something can't be legally sold yet? What 379 00:19:02,877 --> 00:19:07,097 I want to hear is like, what is the thing that wasn't 380 00:19:07,097 --> 00:19:11,317 in the debt for investors that like you created 381 00:19:11,519 --> 00:19:15,563 That had them say, Yes, we're gonna get behind this. I want I wanna 382 00:19:15,563 --> 00:19:17,451 really we like transparency and vulnerability if you're willing to go there and Yeah, 383 00:19:17,451 --> 00:19:19,532 Cody Simmons: understand how that works. Yeah. 384 00:19:19,607 --> 00:19:20,432 Gary Kadi: please. 385 00:19:20,432 --> 00:19:23,768 Cody Simmons: Yeah. I mean, I I think a lot of it again, kind 386 00:19:23,768 --> 00:19:27,103 of back to you know, the the world of drugs and and 387 00:19:27,103 --> 00:19:30,439 devices is, you know, there's just a clear cut medical need. In 388 00:19:30,439 --> 00:19:33,774 our case, I mean, Gary, you're a perfect example. That just impacts 389 00:19:33,774 --> 00:19:35,029 so many people, right? One in five Americans get skin cancer 390 00:19:35,029 --> 00:19:36,838 Gary Kadi: Yeah. Yeah. 391 00:19:37,110 --> 00:19:41,040 Cody Simmons: by the age of 70. five year survival rate is 392 00:19:41,040 --> 00:19:44,971 99% of detected early, 40% if detected at stage four. 393 00:19:44,971 --> 00:19:45,590 Gary Kadi: Mm, mm. 394 00:19:45,590 --> 00:19:45,960 Cody Simmons: So, 395 00:19:45,960 --> 00:19:49,972 you know, it's it's something that people I think can often kind of intuitively 396 00:19:49,972 --> 00:19:53,984 relate to. And like once so often when I tell people about our work 397 00:19:53,984 --> 00:19:57,997 or I show people the device, they're like, that's so obvious. Like, why hasn't 398 00:19:57,997 --> 00:20:01,792 that existed before? That's such a great idea. And it's like, 399 00:20:01,792 --> 00:20:02,092 Gary Kadi: Yeah. 400 00:20:02,269 --> 00:20:05,380 Cody Simmons: well yeah, it's a great idea. It's very hard to do, right? Like 401 00:20:05,380 --> 00:20:08,053 flying cars is a great idea too. Good luck building them, right? So 402 00:20:08,053 --> 00:20:08,368 Gary Kadi: Right. 403 00:20:08,492 --> 00:20:13,903 Cody Simmons: you know, I think that was kind of for us very challenging. 404 00:20:13,903 --> 00:20:18,708 To actually build it and validate it and get through the FDA. And I'll 405 00:20:18,708 --> 00:20:23,514 talk to image-based tools in a minute. But I think just that intrinsic intrinsic, 406 00:20:23,514 --> 00:20:26,867 like this is something that should exist and will be successful. Right? 407 00:20:26,867 --> 00:20:28,082 Gary Kadi: Basic time. Right. 408 00:20:28,319 --> 00:20:32,146 Cody Simmons: Like it may, you know, there may be setbacks on the way, 409 00:20:32,146 --> 00:20:35,974 commercially, you know, reimbursement or channel partners and you know, workflow, changing 410 00:20:35,974 --> 00:20:39,802 physician behavior, how's that all gonna pan out? But one of our 411 00:20:39,802 --> 00:20:43,629 new a great physician collaborator that I spoke with a month ago. 412 00:20:43,629 --> 00:20:47,281 He he he I think said it very aptly, which was 413 00:20:47,281 --> 00:20:50,431 this is going to be the new normal. Like we're 414 00:20:50,431 --> 00:20:50,855 Gary Kadi: Mm-hmm. 415 00:20:50,933 --> 00:20:54,395 Cody Simmons: gonna look back at how we at how we as primary care 416 00:20:54,395 --> 00:20:57,472 doctors used to check skin cancer and be like, man, that 417 00:20:57,472 --> 00:20:57,772 Gary Kadi: Right. 418 00:20:57,857 --> 00:20:59,943 Cody Simmons: was so that was so primitive. Right? Like that that we used to just 419 00:20:59,943 --> 00:21:02,184 Gary Kadi: Yep. yeah, for sure. Yeah. 420 00:21:02,349 --> 00:21:05,951 Cody Simmons: eyeball something that could kill our patients, having no 421 00:21:05,951 --> 00:21:06,251 Gary Kadi: Yeah. 422 00:21:06,482 --> 00:21:09,538 Cody Simmons: ex having no expertise, like very limited training, no expertise, 423 00:21:09,538 --> 00:21:12,595 no specialty, and be like, nah, you're okay. Like 424 00:21:12,697 --> 00:21:16,889 He's like it's it it's just when you just think about where we 425 00:21:16,889 --> 00:21:21,081 will be, it's gonna be whether it's your tool, similar to what you 426 00:21:21,081 --> 00:21:25,273 know, this will be the new normal. And so I think that kind 427 00:21:25,273 --> 00:21:29,464 of having that clear sense of a vision and what the future holds 428 00:21:29,464 --> 00:21:33,656 was definitely helpful. And you know, with there were tough tough honestly, Gary, 429 00:21:33,656 --> 00:21:37,848 in the early days the most challenging aspect wasn't even really selling that 430 00:21:37,848 --> 00:21:42,040 vision that like this is what the future will look like. 431 00:21:42,040 --> 00:21:45,923 It was actually selling that this technology will be the 432 00:21:45,923 --> 00:21:48,267 leader or one of the leaders for that future. Because 433 00:21:48,267 --> 00:21:49,469 Gary Kadi: Mm. 434 00:21:49,945 --> 00:21:54,536 Cody Simmons: articles had just been coming out. It was early, you know, seven, eight 435 00:21:54,536 --> 00:21:58,741 years ago, was the early medical imaging AI stuff. Right. So it's 436 00:21:58,741 --> 00:21:59,041 Gary Kadi: Right. 437 00:21:59,126 --> 00:22:04,157 Cody Simmons: way before Gen AI, but it was when a lot of the predictive diagnostics with 438 00:22:04,157 --> 00:22:08,437 radiology and the first paper on applying algorithms to photos of skin lesions was thirty-five 439 00:22:08,437 --> 00:22:08,890 Gary Kadi: Yeah. 440 00:22:09,188 --> 00:22:10,080 Cody Simmons: years ago. 441 00:22:10,080 --> 00:22:10,380 Gary Kadi: Yeah. 442 00:22:10,265 --> 00:22:11,145 Cody Simmons: And then really started 443 00:22:11,145 --> 00:22:14,406 becoming more and more hot, you know, nine, nine, eight, nine years 444 00:22:14,406 --> 00:22:17,668 ago. Like publications went from okay, five or ten a year to 445 00:22:17,668 --> 00:22:20,929 like a hundred a year. So there's a lot of investors that 446 00:22:20,929 --> 00:22:24,191 are like, why are we underwriting miniaturizing this huge device that you 447 00:22:24,191 --> 00:22:27,452 have to deal with manufacturing issues and miniaturization and you know, supply 448 00:22:27,452 --> 00:22:30,714 chains, blah, blah, blah, when there's papers coming out saying you can 449 00:22:30,714 --> 00:22:33,556 just take a photo from your smartphone and run 450 00:22:33,556 --> 00:22:33,856 Gary Kadi: Right. 451 00:22:33,975 --> 00:22:37,891 Cody Simmons: AI algorithm and that it's as good or better than a dermatologist? 452 00:22:37,891 --> 00:22:38,191 So that was 453 00:22:38,111 --> 00:22:38,411 Gary Kadi: Right. 454 00:22:38,481 --> 00:22:42,471 Cody Simmons: actually our our challenge in the early days. Now that's not so much 455 00:22:42,471 --> 00:22:46,461 our issue because all the there's an order of magnitude more publications, order 456 00:22:46,461 --> 00:22:49,865 of magnitude more companies using image-based approaches, and not a single 457 00:22:49,865 --> 00:22:50,165 Gary Kadi: Right. 458 00:22:50,451 --> 00:22:54,780 Cody Simmons: one is available in the US. they have to standardize lighting, distance, skin of color 459 00:22:54,780 --> 00:22:58,634 is an issue, hair in the way is an issue. And Gary, if you 460 00:22:58,634 --> 00:22:59,052 Gary Kadi: Mm. 461 00:22:59,108 --> 00:23:02,155 Cody Simmons: solve for all of that, great, you're just getting 462 00:23:02,155 --> 00:23:04,808 a photo of the surface of the skin that 463 00:23:04,808 --> 00:23:05,108 Gary Kadi: Right. 464 00:23:05,203 --> 00:23:07,144 Cody Simmons: the doctor's already looking at. Like 465 00:23:07,144 --> 00:23:07,895 Gary Kadi: Right. 466 00:23:07,895 --> 00:23:08,195 Cody Simmons: Cool cool. Yeah, okay. You're 467 00:23:08,101 --> 00:23:08,945 Gary Kadi: It's more of the same. 468 00:23:09,157 --> 00:23:12,893 Cody Simmons: yeah, you're better analyzing the surface of the skin than the doctor's 469 00:23:12,893 --> 00:23:16,629 already looking at, great. But we're actually taking non invasive tissue samples 470 00:23:16,629 --> 00:23:20,365 up to a millimeter beneath the surface of the skin. 471 00:23:20,365 --> 00:23:20,990 Gary Kadi: wow. 472 00:23:20,990 --> 00:23:23,008 Cody Simmons: So that's kind of how our technology works. Yeah, I can 473 00:23:23,008 --> 00:23:24,520 do a demo or or can pop up a slide if 474 00:23:24,520 --> 00:23:25,084 Gary Kadi: Yeah, let's do a 475 00:23:25,084 --> 00:23:28,023 de let's do a quick demo real quick. I think it's good time for that. 476 00:23:28,023 --> 00:23:31,809 Cody Simmons: Yeah, so the device pulses in here. I'll so I'll act like 477 00:23:31,809 --> 00:23:35,594 I'm a doctor and my arm is the patient. And I'll go 478 00:23:35,594 --> 00:23:39,380 into a little more detail than you know a doctor normally would, 479 00:23:39,380 --> 00:23:43,166 just cause, you know, to to share more more details here. But 480 00:23:43,166 --> 00:23:46,951 and I joke, I I was born for this job. I have 481 00:23:46,951 --> 00:23:50,737 a perfect demo mole right on my forearm. It's like five minutes, 482 00:23:50,737 --> 00:23:54,522 and it's funny actually, d dermatologists, not just PCPs, two dermatologists over 483 00:23:54,522 --> 00:23:58,308 the years that have been my dermatologist have wanted a biopsy. 484 00:23:58,308 --> 00:23:58,608 Like, it looks a little funky. 485 00:23:58,387 --> 00:23:59,643 Gary Kadi: wow, perfect. Yeah. 486 00:23:59,649 --> 00:24:04,171 Cody Simmons: And I'm like, you can't biopsy it. It's stayed the same for 487 00:24:04,171 --> 00:24:06,537 a decade, and I need it for my job. So you can't. 488 00:24:06,537 --> 00:24:08,527 Gary Kadi: Right. 489 00:24:08,693 --> 00:24:10,733 Cody Simmons: So I guess maybe I'm putting myself at a little 490 00:24:10,733 --> 00:24:12,180 health risk for the company, but it it's worth it. 491 00:24:12,180 --> 00:24:13,855 Gary Kadi: All right, perfect. 492 00:24:13,855 --> 00:24:17,517 Cody Simmons: So yeah, so just a visual, right? Like I'm a family doctor, right? My arms 493 00:24:17,517 --> 00:24:20,681 me. So okay, Cody, you mentioned you're a little worried about this mole, maybe 494 00:24:20,681 --> 00:24:20,981 Gary Kadi: Yeah. 495 00:24:21,178 --> 00:24:24,491 Cody Simmons: that maybe it's you know, it's a little larger and different than the others. 496 00:24:24,491 --> 00:24:24,791 It it does 497 00:24:24,584 --> 00:24:24,901 Gary Kadi: Right. 498 00:24:25,052 --> 00:24:28,600 Cody Simmons: look, it is a bit larger, it looks a bit different, but it 499 00:24:28,600 --> 00:24:32,149 doesn't have irregular borders, it doesn't have odd colors in it, so it 500 00:24:32,149 --> 00:24:35,697 doesn't have like the classic signs of melanoma. That being said, melanomas can 501 00:24:35,697 --> 00:24:39,246 often be subtle and and and challenging to diagnose. So I'm not confident 502 00:24:39,246 --> 00:24:42,794 saying it's benign because I'm not a dermatologist, right? I'm your family doctor. 503 00:24:42,794 --> 00:24:46,342 we could go ahead and refer you to dermatologist, but you know, I 504 00:24:46,342 --> 00:24:49,891 know you're a busy guy, it's hours off work, a $50 to $100 505 00:24:49,891 --> 00:24:53,439 copay, many areas is a couple months wait time. 506 00:24:53,439 --> 00:24:56,481 the good news is we just got this new device that was 507 00:24:56,481 --> 00:24:59,522 cleared by the FDA. There's many published studies, and two of them 508 00:24:59,522 --> 00:25:01,061 show head to head it's as accurate as in-person dermatologists. 509 00:25:01,061 --> 00:25:02,420 Gary Kadi: It edited accurate different. 510 00:25:02,564 --> 00:25:05,960 Cody Simmons: It's called dermasensor, and it works by non-invasively scanning the skin lesion 511 00:25:05,960 --> 00:25:08,808 Gary Kadi: I think that you have to leave them. 512 00:25:08,808 --> 00:25:15,742 Cody Simmons: to see are there any signs of cancer within the cells beneath the surface of the 513 00:25:15,742 --> 00:25:17,871 Gary Kadi: Got it. Yeah. Yeah. 514 00:25:17,871 --> 00:25:20,332 Cody Simmons: So I'm gonna go ahead here and touch the screen and wakes up. 515 00:25:22,947 --> 00:25:23,836 That's a calibration step, just making sure nothing's blocking 516 00:25:23,836 --> 00:25:25,789 Gary Kadi: I'll take the back in that. Got it. 517 00:25:25,789 --> 00:25:28,632 Cody Simmons: the probe tip because the device works by emitting 518 00:25:28,632 --> 00:25:33,172 light and detecting what comes back. There's a spectrometer here in the device. So here 519 00:25:33,172 --> 00:25:33,472 Gary Kadi: Okay. 520 00:25:33,516 --> 00:25:36,482 Cody Simmons: I'll scan here. You can kind of see how the light flashes. 521 00:25:36,482 --> 00:25:37,861 Gary Kadi: yeah, so I yeah. 522 00:25:37,861 --> 00:25:41,519 Cody Simmons: Yeah, the video doesn't really catch it exactly, but it's almost like a ballpoint 523 00:25:41,519 --> 00:25:42,270 pen tip with like a little flashlight coming out, but a very yeah, 524 00:25:42,270 --> 00:25:44,339 Gary Kadi: Yeah. Yeah, we saw a flash. 525 00:25:45,177 --> 00:25:47,614 Cody Simmons: it's a it's a xenon lamp. It's pulsing hundreds 526 00:25:47,614 --> 00:25:50,052 of different wavelengths, right? We see in three wavelengths. 527 00:25:50,052 --> 00:25:54,050 This is pulsing hundreds of different wavelengths. And so it's assessing the 528 00:25:54,050 --> 00:25:58,049 same things that a pathologist will look at under a microscope. For 529 00:25:58,049 --> 00:26:02,047 example, if cells have enlarged nuclei, they're gonna absorb more light, more 530 00:26:02,047 --> 00:26:06,046 photons at certain wavelengths. So that's what the spectral curves that result 531 00:26:06,046 --> 00:26:10,044 from this, the inventor, be you, Professor Irving Biggio, he can like 532 00:26:10,044 --> 00:26:14,043 read the curves. Like, yeah, this has enlarged nuclei. There's more presence 533 00:26:14,043 --> 00:26:18,041 of condensed chromatin in this one. It looks like the, 534 00:26:18,041 --> 00:26:21,534 Carotinocytes are more dense and like because he knows what features 535 00:26:21,534 --> 00:26:25,026 correspond to what wavelengths and levels. So, okay, great. So, so 536 00:26:25,026 --> 00:26:28,518 then it gave me an error message because it knows I'm 537 00:26:28,518 --> 00:26:31,503 not holding it up to the lesion. So we have some 538 00:26:31,503 --> 00:26:31,980 Gary Kadi: Got it. 539 00:26:32,011 --> 00:26:34,972 Cody Simmons: cool usability. So it's like, put it on the lesion, idiot. 540 00:26:34,972 --> 00:26:35,367 Gary Kadi: Nice. 541 00:26:35,904 --> 00:26:39,082 Cody Simmons: so go ahead and take five different tissue samples. Each one is measuring 542 00:26:39,082 --> 00:26:39,398 Gary Kadi: Okay. 543 00:26:39,517 --> 00:26:42,537 Cody Simmons: about a millimeter tissue non-invasively, and 544 00:26:42,537 --> 00:26:42,837 Gary Kadi: Yeah. 545 00:26:42,949 --> 00:26:46,029 Cody Simmons: I'm picking it up, putting it down in different parts of the mole. 546 00:26:46,029 --> 00:26:46,329 The same way a pathologist 547 00:26:46,314 --> 00:26:46,630 Gary Kadi: Okay. 548 00:26:47,389 --> 00:26:50,615 Cody Simmons: will look at different parts of the biopsy tissue under 549 00:26:50,615 --> 00:26:50,996 microscope. Right? So kind of sampling different. And now the 550 00:26:50,996 --> 00:26:53,735 Gary Kadi: Got it. So it's really the same thing. Yeah. 551 00:26:53,841 --> 00:26:58,750 Cody Simmons: FDA approved algorithms processing the data to see is there any cancer risk. Nope. Monitor. So monitors 552 00:26:58,750 --> 00:26:59,825 Gary Kadi: Got it. Yep. 553 00:27:00,103 --> 00:27:02,569 Cody Simmons: the negative result. That's like zero. A positive 554 00:27:02,569 --> 00:27:02,912 Gary Kadi: Right. 555 00:27:02,994 --> 00:27:08,466 Cody Simmons: result to investigate further says, okay, there's some chance of cancer, but this scale 556 00:27:08,466 --> 00:27:10,288 Gary Kadi: Yep. Yep. Got it. 557 00:27:10,386 --> 00:27:13,593 Cody Simmons: on a one to ten scale. And the likelihood of cancer. 558 00:27:13,593 --> 00:27:17,522 For monitor, depending which study you read, was 97 to 100%. the 559 00:27:17,522 --> 00:27:21,452 likelihood of cancer for positive results investigate further, one to 10. And 560 00:27:21,452 --> 00:27:25,381 the pivotal study with over a thousand patients, 22 study centers led 561 00:27:25,381 --> 00:27:29,310 by Mail Clinic, was 6% for a score of one and 61% 562 00:27:29,310 --> 00:27:33,239 for score of 10. So a 10-fold difference in cancer likelihood. And 563 00:27:33,239 --> 00:27:37,169 you do this quick non-invasive process, and now you as a doctor, 564 00:27:37,169 --> 00:27:41,098 you know where the mole falls on that risk continuum. 565 00:27:41,098 --> 00:27:44,718 Gary Kadi: That's fantastic. Congratulations and thanks for sharing that. That is that is really 566 00:27:44,718 --> 00:27:48,338 magnificent. And and it makes it doable for a a physician who has, 567 00:27:48,338 --> 00:27:51,958 you know, PCP, who has very few you know, doesn't have a lot 568 00:27:51,958 --> 00:27:55,577 of time. That was clear that that was pretty quick and and and 569 00:27:55,577 --> 00:27:59,197 knowing it's accurate and approved by FDA is is rock solid. So I 570 00:27:59,197 --> 00:28:02,817 have two more questions for you. And man, I can't believe it. We 571 00:28:02,817 --> 00:28:04,821 only have five minutes left. Cody, what the heck happened? 572 00:28:04,821 --> 00:28:05,662 Cody Simmons: wow. Okay. 573 00:28:06,437 --> 00:28:08,100 Gary Kadi: So I want to make sure we 574 00:28:08,100 --> 00:28:12,030 the audience here is these two because when I analyzed the questions I 575 00:28:12,030 --> 00:28:15,961 thought would be interesting to our audience in addition to your great you 576 00:28:15,961 --> 00:28:19,891 know device, two questions I have. One is on trust. You know, you're 577 00:28:19,891 --> 00:28:23,822 a bioengineer, you're selling to physicians. What did you have to learn about 578 00:28:23,822 --> 00:28:27,752 earning trust from people with people that have more training than you? Like 579 00:28:27,752 --> 00:28:31,683 what did you learn about about this earning of trust? Cause if you 580 00:28:31,683 --> 00:28:35,613 didn't earn trust through this whole process, 581 00:28:35,613 --> 00:28:38,905 You know, this wouldn't come to fruition. It never would have 582 00:28:38,905 --> 00:28:42,197 come to reality in a in a company. Give us a 583 00:28:42,197 --> 00:28:45,489 few insights that you learned along the journey of like how 584 00:28:45,489 --> 00:28:48,781 you learned how to build trust with people around you. 585 00:28:48,781 --> 00:28:52,416 Cody Simmons: Yeah, I mean I I think it's tough, right? 'Cause you have 586 00:28:52,416 --> 00:28:56,050 to strike that balance of kind of being a leader and, you 587 00:28:56,050 --> 00:28:59,684 know, kind of showing you you can make this vision happen, but 588 00:28:59,684 --> 00:29:02,877 also people not thinking you're you're full of hot air. and 589 00:29:02,877 --> 00:29:03,206 Gary Kadi: Yeah. 590 00:29:03,319 --> 00:29:05,959 Cody Simmons: especially when you're an a younger entrepreneur and a first 591 00:29:05,959 --> 00:29:06,320 Gary Kadi: Yeah. Yeah. 592 00:29:06,320 --> 00:29:09,322 Cody Simmons: time entrepreneur, which I was both, it can be particularly, 593 00:29:09,402 --> 00:29:12,824 particularly tough. So I think for me, for me the is that there 594 00:29:12,824 --> 00:29:16,125 a noise coming through by the way, or can you hear me fine? 595 00:29:16,125 --> 00:29:17,927 Gary Kadi: Yeah, I hear a little bit. Yep. 596 00:29:17,927 --> 00:29:18,585 Cody Simmons: Okay. 597 00:29:18,585 --> 00:29:18,976 my headphones on. 598 00:29:18,976 --> 00:29:19,276 Gary Kadi: It 599 00:29:19,459 --> 00:29:25,295 Cody Simmons: For me, I think the key thing sorry. 600 00:29:25,295 --> 00:29:27,777 You want me to re answer this by the way or 601 00:29:27,777 --> 00:29:33,118 Gary Kadi: no you can go right through. You're good. It wasn't that bad. I like the authenticity. 602 00:29:33,118 --> 00:29:34,036 Cody Simmons: you can't hear it anymore. 603 00:29:34,243 --> 00:29:37,615 Gary Kadi: Yeah, no, you're good. I can hear a little bit, but we can 604 00:29:37,615 --> 00:29:38,199 Cody Simmons: Okay, I'm on 605 00:29:38,317 --> 00:29:42,640 Gary Kadi: keep go Yeah, we can keep going. 606 00:29:42,640 --> 00:29:46,828 Cody Simmons: Okay, so so for me, the key thing I think and 607 00:29:46,828 --> 00:29:50,813 kind of mindset to have is is confident but humble. 608 00:29:50,813 --> 00:29:51,135 Gary Kadi: Yep. 609 00:29:51,135 --> 00:29:51,435 Yep. 610 00:29:51,428 --> 00:29:52,789 Cody Simmons: You know, think humility 611 00:29:52,789 --> 00:29:56,771 and the nice thing was, yeah, I kinda had a personal family 612 00:29:56,771 --> 00:30:00,039 history and involvement with skin cancer, but professionally, right? I wasn't a 613 00:30:00,039 --> 00:30:00,754 Gary Kadi: Right. Right. Exactly. 614 00:30:00,754 --> 00:30:04,736 Cody Simmons: dermatologist, wasn't a primary care doctor, I had no sh 615 00:30:04,736 --> 00:30:07,388 so you know, so everything I learned was kind of 616 00:30:07,388 --> 00:30:09,586 osmosis from experts in the field, right? And I 617 00:30:09,586 --> 00:30:10,010 Gary Kadi: Yeah. 618 00:30:10,039 --> 00:30:16,403 Cody Simmons: and as an engineer in economics background was used to kind of just synthesizing and analyzing. 619 00:30:16,543 --> 00:30:16,851 So 620 00:30:16,851 --> 00:30:17,183 Gary Kadi: Right. 621 00:30:17,344 --> 00:30:21,447 Cody Simmons: I think that's, you know, especially when you're in a new area, 622 00:30:21,447 --> 00:30:25,550 you know, stay stay humble, stay open. But you also obviously have 623 00:30:25,550 --> 00:30:29,653 to have that level of confidence in you know, taking account a 624 00:30:29,653 --> 00:30:33,756 lot of feedback. We've, you know, talked to a lot of the 625 00:30:33,756 --> 00:30:36,989 experts. Here's a various opinion, sometimes they differed, but 626 00:30:36,989 --> 00:30:37,587 Gary Kadi: But definitely. 627 00:30:37,859 --> 00:30:41,395 Cody Simmons: here's the best plan and here's why, and we're gonna be successful. Right. I think that's kind 628 00:30:41,395 --> 00:30:41,727 Gary Kadi: Yeah. 629 00:30:41,782 --> 00:30:44,077 Cody Simmons: of generally the the MO and 630 00:30:44,077 --> 00:30:48,831 And you know, you really gotta practice what you preach, right? There's we've seen 631 00:30:48,831 --> 00:30:53,585 other companies that have really tried to cut corners and and I we have 632 00:30:53,585 --> 00:30:57,981 not when it comes to clinical data, especially, right? You know, really robust 633 00:30:57,981 --> 00:30:58,281 Gary Kadi: Yep. 634 00:30:58,339 --> 00:31:01,831 Cody Simmons: studies, really upfront with the FDA, you know, multiple pre submission 635 00:31:01,831 --> 00:31:05,323 meetings before we did the studies and we do the studies, 636 00:31:05,323 --> 00:31:08,815 you know, and and share all those results and 637 00:31:08,815 --> 00:31:12,602 We got grilled with questions for back and forth for many 638 00:31:12,602 --> 00:31:14,652 months. I got shingles during it. That was fun. yeah, yeah. 639 00:31:14,652 --> 00:31:16,173 Gary Kadi: boy. 640 00:31:16,388 --> 00:31:19,437 Cody Simmons: So very very long, intense process. But you know, at the 641 00:31:19,437 --> 00:31:22,486 day, at the end of the day, right, that that commitment 642 00:31:22,486 --> 00:31:25,201 to high quality studies and evidence and their trust in in 643 00:31:25,201 --> 00:31:25,534 Gary Kadi: Their tracks and technology that people are involved. Yep. 644 00:31:25,534 --> 00:31:28,583 Cody Simmons: the company and the people involved is part of their their 645 00:31:28,583 --> 00:31:32,735 decision making process, right? Cause they don't want to prove especially a first 646 00:31:32,735 --> 00:31:34,651 in class product for cancer for use by people who are not experts. 647 00:31:34,651 --> 00:31:37,646 Gary Kadi: Yep. 648 00:31:37,646 --> 00:31:37,946 Cody Simmons: Right, there's a lot of reasons for them to be pretty concerned with that. 649 00:31:37,767 --> 00:31:41,914 Gary Kadi: Right. I think for a lot of reasons for them to be pretty concerned with 650 00:31:41,914 --> 00:31:42,214 that. especially after the full stock inventory to block all the whole bit of 651 00:31:42,019 --> 00:31:46,391 Cody Simmons: especially after the pulse oxymetry debacle had just unfolded. It was months after that 652 00:31:46,391 --> 00:31:51,635 the medical community was like, wait, pulse oxymetry isn't accurate on African Americans. That's a problem. Right. 653 00:31:51,635 --> 00:31:53,453 Gary Kadi: Yeah. 654 00:31:53,524 --> 00:31:57,193 Cody Simmons: Yeah. And so they directly told us kind of during the review, 655 00:31:57,193 --> 00:32:00,861 they're like, Yeah, we we do not want to prove something that 656 00:32:00,861 --> 00:32:03,601 we later find out doesn't work on certain ethnicities. Like that is 657 00:32:03,601 --> 00:32:04,429 Gary Kadi: Right. 658 00:32:04,530 --> 00:32:07,225 Cody Simmons: so you know, they they 659 00:32:07,225 --> 00:32:11,866 Part of the back and forths was, okay, we get the technical literature, and 660 00:32:11,866 --> 00:32:16,508 also your studies don't suggest that there's any impact of device performance on skin 661 00:32:16,508 --> 00:32:18,631 of color, right? Because you're not assessing the visual appearance, you're assessing cellular 662 00:32:18,631 --> 00:32:21,126 Gary Kadi: Mm-hmm. Right. 663 00:32:21,149 --> 00:32:24,885 Cody Simmons: level information, but you don't have tons of cancers in 664 00:32:24,885 --> 00:32:26,279 darker skin types because they're way less common, right? So 665 00:32:26,279 --> 00:32:28,338 Gary Kadi: Mm-hmm. Yep. 666 00:32:28,661 --> 00:32:30,697 Cody Simmons: we won't restrict the device from use in darker skin types, but we want 667 00:32:30,697 --> 00:32:32,852 Gary Kadi: we want you to do post market survey on it. 668 00:32:32,852 --> 00:32:37,043 Cody Simmons: you to do post-market surveillance to actually collect more data and show that. 669 00:32:37,293 --> 00:32:37,717 Especially for melanoma. So that was kind of where things netted out with the FDA. 670 00:32:37,717 --> 00:32:41,806 Gary Kadi: Right. 671 00:32:41,806 --> 00:32:45,118 Cody Simmons: And and and a lot of companies get asked to do that and then 672 00:32:45,118 --> 00:32:46,297 they just don't. They don't do the studies. So, you know, I think 673 00:32:46,297 --> 00:32:48,269 Gary Kadi: Right. Yeah, yeah, yeah. 674 00:32:48,431 --> 00:32:51,236 Cody Simmons: part of it was a trust, like, you know, given all the work 675 00:32:51,236 --> 00:32:51,817 we had done, we submitted six clinical studies to the FDA in total. 676 00:32:51,817 --> 00:32:54,041 Gary Kadi: I don't know, you know, we'd be 677 00:32:54,041 --> 00:32:56,846 Cody Simmons: And they're like, okay, you know, we we how this company 678 00:32:56,846 --> 00:33:00,734 operates and having gotten to know them over eight years of meetings, 679 00:33:00,734 --> 00:33:01,059 Gary Kadi: Right. 680 00:33:01,079 --> 00:33:04,201 Cody Simmons: you know, we believe they'll actually be able to, you know, 681 00:33:04,201 --> 00:33:07,323 conduct a study and that it's safe to to approve. 682 00:33:07,323 --> 00:33:10,428 Gary Kadi: And I I think there's one thing that you didn't mention that 683 00:33:10,428 --> 00:33:13,534 I've experienced with you is you're a man of your word. You 684 00:33:13,534 --> 00:33:16,639 showed up like ready to go. You were a minute, I think 685 00:33:16,639 --> 00:33:19,744 you were a minute or two late. You acknowledged that you were 686 00:33:19,744 --> 00:33:22,850 late, like you're a man of your word. And, you know, through 687 00:33:22,850 --> 00:33:25,955 eight years of demonstrating integrity, personal integrity, also for me in my 688 00:33:25,955 --> 00:33:29,060 experience, that's probably why you're very successful in what you do as 689 00:33:29,060 --> 00:33:32,166 well. Just in my own experience of your your trust, the trust 690 00:33:32,166 --> 00:33:34,351 that you built with me. So yeah, pretty cool. 691 00:33:34,351 --> 00:33:35,292 Cody Simmons: I appreciate that. Yeah, I'm 692 00:33:35,292 --> 00:33:38,890 not I'm not great at always being on time, but I always just so much 693 00:33:38,890 --> 00:33:41,361 going on, but I always make sure to apologize when I'm not 'cause yeah. 694 00:33:41,361 --> 00:33:42,552 Gary Kadi: Yeah, no, that's your man of 695 00:33:42,552 --> 00:33:45,835 your word. Like that's pretty that's that that little nuance. Somebody might 696 00:33:45,835 --> 00:33:49,119 just step over that. And my experience was like, and I had 697 00:33:49,119 --> 00:33:52,402 to adjust my calendar and you you adjusted and we worked it 698 00:33:52,402 --> 00:33:55,686 out. So I just noticed you operate from a foundation of integrity. 699 00:33:55,686 --> 00:33:58,319 And I think that that's really powerful too, Cody. 700 00:33:58,319 --> 00:33:58,731 Cody Simmons: Thank you. 701 00:33:59,069 --> 00:34:02,972 Gary Kadi: Last here, you're welcome. Last question. Most founders underestimate this gap, 702 00:34:02,972 --> 00:34:06,875 I find. And I I'm gonna ask you this question. 703 00:34:06,875 --> 00:34:09,731 What broke first when you when you cleared to actually 704 00:34:09,731 --> 00:34:11,757 start selling? Like what was the what was the break 705 00:34:11,757 --> 00:34:12,204 Cody Simmons: Yeah. 706 00:34:12,588 --> 00:34:16,239 Gary Kadi: that happened for you when you started to scale? 707 00:34:16,239 --> 00:34:20,463 Cody Simmons: hmm. Yeah, I mean, well, so there's two I'll I'll cover two 708 00:34:20,463 --> 00:34:24,687 quickly. Our first big issue, which ended up being a blessing in 709 00:34:24,687 --> 00:34:28,553 disguise, was we didn't have product supply. So we'd worked 710 00:34:28,553 --> 00:34:28,893 Gary Kadi: Mm. 711 00:34:28,911 --> 00:34:33,042 Cody Simmons: with kind of small local design firm doing the final miniaturization work and kind of small 712 00:34:33,042 --> 00:34:33,371 Gary Kadi: Right. 713 00:34:33,505 --> 00:34:35,625 Cody Simmons: batch manufacturing, but post COVID they lost some of their top engineers. They like went bankrupt. Ultimately 714 00:34:35,625 --> 00:34:37,498 Gary Kadi: They lost a five cars they like. 715 00:34:37,769 --> 00:34:40,481 Cody Simmons: they still owe us hundreds of thousands of dollars, actually. 716 00:34:40,481 --> 00:34:40,781 Gary Kadi: wow. 717 00:34:41,202 --> 00:34:43,107 Cody Simmons: so yeah, so that's fun. 718 00:34:43,107 --> 00:34:43,486 so 719 00:34:43,486 --> 00:34:43,786 Gary Kadi: Yeah. 720 00:34:44,308 --> 00:34:46,097 Cody Simmons: we switched to a bigger firm, but that wasn't ready 721 00:34:46,097 --> 00:34:46,730 Gary Kadi: Probably that wasn't ready in my following threat. Okay. 722 00:34:46,730 --> 00:34:49,152 Cody Simmons: in time following clearance. So we didn't have devices 723 00:34:49,152 --> 00:34:53,505 at clearance. Of course, sales team commercially were, you know, there's frustration 724 00:34:53,505 --> 00:34:57,859 and in retrospect, such a so so helpful that we had not 725 00:34:57,859 --> 00:35:02,212 just a few months before FDA clearance, but time post FDA clearance 726 00:35:02,212 --> 00:35:06,566 to actually prepare, start initial discussions, you know, lock in some of 727 00:35:06,566 --> 00:35:10,919 the sales processes, training material for customers, et cetera. 728 00:35:10,919 --> 00:35:14,899 to actually when we start delivering devices make that successful. so I think that's 729 00:35:14,899 --> 00:35:15,237 Gary Kadi: Mm-hmm. 730 00:35:15,272 --> 00:35:18,653 Cody Simmons: something, since I know a lot of your audience as entrepreneurs, 731 00:35:18,653 --> 00:35:19,551 Gary Kadi: Yeah. Right. Right. Right. 732 00:35:19,551 --> 00:35:23,831 Cody Simmons: to really be thoughtful about is just because you can hit 733 00:35:23,831 --> 00:35:28,110 go from a regulatory standpoint, do you actually want to? Right? 734 00:35:28,110 --> 00:35:31,865 so kind of how much time does the team the need and 735 00:35:31,865 --> 00:35:35,620 and this one isn't isn't new, but when you hit go 736 00:35:35,620 --> 00:35:39,311 That's also when the clock starts in terms of investors counting. 737 00:35:39,311 --> 00:35:40,998 How are they doing sales-wise? Right. And I think that's 738 00:35:40,998 --> 00:35:42,780 Gary Kadi: Right, right. Right. 739 00:35:43,002 --> 00:35:46,717 Cody Simmons: the other challenge. Like that, like I used to be so I was frustrated. I'm 740 00:35:46,717 --> 00:35:50,087 like, man, we've got to get FDA clearance in 2023. Right. Like it'll be so 741 00:35:50,087 --> 00:35:50,387 Gary Kadi: Yeah. 742 00:35:50,433 --> 00:35:53,154 Cody Simmons: embarrassing if it's and now I'm like, thank God 743 00:35:53,154 --> 00:35:55,495 we didn't get clearance in 2023. Cause now when 744 00:35:55,495 --> 00:35:55,795 Gary Kadi: Right. 745 00:35:55,875 --> 00:35:58,307 Cody Simmons: we talk about, how many years have you been on the market 746 00:35:58,307 --> 00:36:00,739 and what are your sales levels and how you ramp it up? 747 00:36:00,739 --> 00:36:03,171 Like, yeah, we got clearance in 2024. First sale was mid that 748 00:36:03,171 --> 00:36:05,603 year. You know, we're we're ramping up quickly, blah, blah, blah. 749 00:36:05,603 --> 00:36:09,359 Right. If like, yeah, clearance twenty twenty three, it kind of puts 750 00:36:09,359 --> 00:36:13,115 an extra almost expectation on, you know, where sales levels and partnerships 751 00:36:13,115 --> 00:36:16,871 and stuff should be. so I think that was the next one 752 00:36:16,871 --> 00:36:20,627 in terms of what broke was quickly realizing we can't do this 753 00:36:20,627 --> 00:36:24,383 alone. There's three hundred thousand primary care physicians at a hundred and 754 00:36:24,383 --> 00:36:28,139 forty thousand locations in the US. How the hell do you effectively 755 00:36:28,139 --> 00:36:31,895 scale to those? I mean, you can't. 756 00:36:31,895 --> 00:36:35,132 and you know, as a small startup, like, yeah, we we've 757 00:36:35,132 --> 00:36:38,368 ultimately raised over forty million dollars, but the kind of round 758 00:36:38,368 --> 00:36:41,604 to commercialize was a bit over ten million. Like you you 759 00:36:41,604 --> 00:36:44,114 can't hire two hundred sales reps with that. Right. 760 00:36:44,114 --> 00:36:44,429 Gary Kadi: Right. 761 00:36:44,841 --> 00:36:48,725 Cody Simmons: So, you know, for us it was like, okay, digital marketing, the 762 00:36:48,725 --> 00:36:52,609 majority of our sales comes through that, you know, leads generated by 763 00:36:52,609 --> 00:36:56,493 digital marketing. you know, our sales reps obviously did some of their 764 00:36:56,493 --> 00:37:00,377 own outreach, you know, through email and LinkedIn and other other avenues. 765 00:37:00,377 --> 00:37:04,438 But what we're announcing, actually, sorry, this podcast will be 766 00:37:04,438 --> 00:37:07,877 aired in couple weeks. So what we announced recently was 767 00:37:07,877 --> 00:37:08,241 Gary Kadi: Okay. 768 00:37:08,499 --> 00:37:10,792 Cody Simmons: some major channel partnerships. 769 00:37:10,792 --> 00:37:11,092 Gary Kadi: Okay. 770 00:37:12,732 --> 00:37:15,663 Cody Simmons: one is with one of the largest distributors in the 771 00:37:15,663 --> 00:37:18,236 country. They have hundreds of sales reps, call on 772 00:37:18,236 --> 00:37:18,553 Gary Kadi: Great. 773 00:37:18,594 --> 00:37:22,821 Cody Simmons: tens of thousands of primary care locations. so they're very excited about 774 00:37:22,821 --> 00:37:26,738 you know adding this Time magazine best invention now, you know, 775 00:37:26,738 --> 00:37:27,038 Gary Kadi: Yeah. 776 00:37:27,048 --> 00:37:29,659 Cody Simmons: automated skin cancer scanner, right, to sales reps. 777 00:37:29,879 --> 00:37:34,453 Bag and we're also working with a contract sales force called MTMC, 778 00:37:34,453 --> 00:37:36,486 MedTech Medicare, which has over 100 sales reps and many of 779 00:37:36,486 --> 00:37:39,020 Gary Kadi: Yep. Great. 780 00:37:39,027 --> 00:37:43,467 Cody Simmons: them are focused on primary care. also a reseller to the VA called 781 00:37:43,467 --> 00:37:47,495 Medical Place that's been selling to them for over 40 years. We're excited 782 00:37:47,495 --> 00:37:47,887 Gary Kadi: Nice. 783 00:37:47,907 --> 00:37:52,852 Cody Simmons: about that partnership. And lastly, I can't name them, but one of the 784 00:37:52,852 --> 00:37:57,798 largest health systems in the country, really in the world, that employs 785 00:37:57,798 --> 00:38:01,030 or or health networks that employs tens of thousands 786 00:38:01,030 --> 00:38:02,056 of primary care doctors. So yeah, so I think 787 00:38:02,056 --> 00:38:04,197 Gary Kadi: That's great. Yep. 788 00:38:04,262 --> 00:38:08,669 Cody Simmons: with those kind of partnerships in place now we're really well positioned to the scale. 789 00:38:08,669 --> 00:38:09,099 Gary Kadi: Yeah, no, 790 00:38:09,099 --> 00:38:12,769 it's fantastic. Congratulations. And if you know, outside of this, if you 791 00:38:12,769 --> 00:38:16,440 wanted to have a conversation about distribution and and sales and marketing, 792 00:38:16,440 --> 00:38:20,110 I I have a lot of channels that I'm I've been over 793 00:38:20,110 --> 00:38:20,759 the years connected to. If you wanted to do a separate 794 00:38:20,759 --> 00:38:23,851 Cody Simmons: Okay. Yeah, no, you've had a lot 795 00:38:23,851 --> 00:38:26,300 of success in in this kind of world. So no, it'd 796 00:38:26,300 --> 00:38:26,739 Gary Kadi: Yeah, this is my jam. Yeah, if you wanna do 797 00:38:26,739 --> 00:38:29,276 Cody Simmons: be great to chat. Maybe we'll have a call. Yeah, with 798 00:38:29,276 --> 00:38:29,628 Gary Kadi: that. Yeah, yeah, yeah. If you wanna if you 799 00:38:29,628 --> 00:38:32,516 Cody Simmons: our SVP of sales. And and I forgot to mention, 800 00:38:32,516 --> 00:38:35,897 yeah, we we also just launched a so we raised sixteen million in 801 00:38:35,897 --> 00:38:39,278 the series B and we just opened up because we have so many, 802 00:38:39,278 --> 00:38:42,659 you know, patients and customers and you know, I don't know six thousand 803 00:38:42,659 --> 00:38:46,040 LinkedIn followers now. And a lot of them often ask, Hey, can we 804 00:38:46,040 --> 00:38:49,421 invest? Like how can we get more involved? We love what you're doing. 805 00:38:49,421 --> 00:38:53,425 So we just on the back of our series B put up a WeFunder campaign. 806 00:38:53,425 --> 00:38:53,807 Gary Kadi: Great. 807 00:38:53,835 --> 00:38:57,693 Cody Simmons: that's also, you know, if there's listeners interested, you know, we've 808 00:38:57,693 --> 00:39:01,551 had everywhere from the $500 to $100,000 investment so far. We've 809 00:39:01,551 --> 00:39:05,409 raised well this podcast will be a little delayed, but $850,000 810 00:39:05,409 --> 00:39:08,360 in the first few weeks. so we're excited, you our 811 00:39:08,360 --> 00:39:09,168 Gary Kadi: Congratulations. 812 00:39:09,267 --> 00:39:13,383 Cody Simmons: whole thing's right, democratizing access to effective skin cancer checks. So kind of 813 00:39:13,383 --> 00:39:13,683 Gary Kadi: Yep. 814 00:39:13,931 --> 00:39:19,282 Cody Simmons: also democratizing access to who can invest in that, not just, you know, VCs and family offices. 815 00:39:19,282 --> 00:39:19,582 Gary Kadi: Great. 816 00:39:19,498 --> 00:39:21,587 Cody Simmons: Made a lot of sense for us. 817 00:39:21,587 --> 00:39:25,270 Gary Kadi: for sure. I love that. so how how could someone get in touch with 818 00:39:25,270 --> 00:39:28,953 you? just let's make sure we we get that in our notes here. 819 00:39:28,953 --> 00:39:32,562 Cody Simmons: Sure, yeah. LinkedIn I'm actually pretty responsive. so you 820 00:39:32,562 --> 00:39:32,868 Gary Kadi: Great. 821 00:39:32,987 --> 00:39:36,028 Cody Simmons: know, Cody Simmons Dermosensor I'd pop right up. and also my email, Cody.simmons 822 00:39:36,028 --> 00:39:37,740 Gary Kadi: Yep. 823 00:39:38,593 --> 00:39:40,562 Cody Simmons: at dermasensor.com, also works well. 824 00:39:40,562 --> 00:39:40,952 Gary Kadi: Great. 825 00:39:40,952 --> 00:39:44,715 Great. Well, Cody, this has been extraordinary. I thank you for 826 00:39:44,715 --> 00:39:48,478 taking the time out. Thank you for creating such a great 827 00:39:48,478 --> 00:39:52,240 product and a company that is gonna really change people's lives. 828 00:39:52,240 --> 00:39:56,003 And we're very grateful to have you on the Delegate podcast. 829 00:39:56,003 --> 00:39:59,279 Cody Simmons: Gary, my pleasure. And yeah, my our our marketing team, you 830 00:39:59,279 --> 00:40:02,556 know, we get hit with kind of podcast invites all the 831 00:40:02,556 --> 00:40:04,594 time, one or two a week. And the marketing team, 832 00:40:04,594 --> 00:40:05,676 Gary Kadi: Yep. 833 00:40:05,832 --> 00:40:08,624 Cody Simmons: when I forwarded yours was very excited. They said, Yeah, no, this is really impressive. 834 00:40:08,624 --> 00:40:10,525 Gary Kadi: Yeah, but I'm talking about Great. 835 00:40:10,536 --> 00:40:14,330 Cody Simmons: the the podcast folks and guests he has on and also the audience. 836 00:40:14,330 --> 00:40:18,123 So you you definitely gotta do it. So thank you for including me. 837 00:40:18,782 --> 00:40:22,092 Gary Kadi: You bet. Thanks. And we'll get this out to you and have a great 838 00:40:22,092 --> 00:40:25,263 day and keep making a difference for people. And stay out of the sun, 839 00:40:25,263 --> 00:40:25,563 Cody Simmons: Good. Thanks, Gary. 840 00:40:25,402 --> 00:40:28,712 Gary Kadi: me. I'll say that to myself. Have a great one. Thanks, Cody. 841 00:40:29,713 --> 00:40:31,709 Bye now.